

### PRESS RELEASE

## Combined general meeting for Cellectis shareholders on June 22nd, 2012

# Approval of the 27 resolutions put forward by the Board of Directors

Paris, June 25th, 2012 (6pm) - Cellectis (Alternext: ALCLS) held its combined general meeting on Friday June 22nd, 2012 at Palais Brongniart in Paris.

Following the voting process, all the resolutions submitted for approval by the Company's shareholders were adopted. With the exception of Resolution 27, all the resolutions were approved with over 91% of the votes.

More specifically, Cellectis' shareholders were invited to give their opinion on the following:

- Approval of the corporate and consolidated financial statements for the year ended December 31st, 2011;
- Approval of regulated agreements;
- Reappointment of Messrs André Choulika, David Sourdive and Alain Godard as directors, alongside the company Kaminvest Holding SAL;
- Reappointment of Institut Pasteur as a non-voting director;
- Approval of a share buyback program and authorization for the Board of Directors to cancel shares acquired under this program;
- Various delegations of authority and financial authorizations for the Board of Directors.

The full voting results are available (in French) on the Company's website (www.cellectis.com).

The general meeting also represented an opportunity for André Choulika, Chairman and CEO, and Marc Le Bozec, Chief Financial Officer, to report to shareholders on the Group's activities, the Board of Directors' work and the Company's governance. They once again confirmed the outlook for the Group looking ahead to 2014.

#### **About Cellectis**

Cellectis improves the quality of life by applying its know-how in genome engineering to a broad range of applications, including human therapeutics, biological and agricultural research. Cellectis is listed on the Paris NYSE-Euronext Alternext market (code: ALCLS).

For more information, visit www.cellectis.com.

#### **Disclaimer**

This message, and the information it contains, is neither an offer to the public, nor a sales or subscription proposal for Cellectis shares in any country whatsoever.



### For further information, please contact:

Cellectis

Philippe Valachs Secretary General Tel: +33 (0)1 81 69 16 00

media@cellectis.com

Calyptus

Alexis Breton / Cyril Combe Tel: +33 (0)1 53 65 68 68 cellectis@calyptus.net